Status:
COMPLETED
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Diabetic Neuropathies
Depressive Disorder, Major
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 m...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Present with pain due to bilateral peripheral neuropathy (according to International Statistical Classification of Diseases and Related Health Problems 10 (ICD 10).
- To qualify for the MDD+ cohort, patients need to meet the ICD-10 criteria for MDD. Furthermore, Hamilton rating scale for depression 17 (HAMD-17) scores need to match with the ICD-10 criteria for qualification of the MDD+ or MDD- groups.
- Male or female outpatients at least 18 years of age.
- Females with child bearing potential must test negative for a serum pregnancy test at Visit 1. Females of child-bearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must agree to utilize medically acceptable and reliable means of birth control as determined by the investigator during the study and for 1 month following the last dose of the study. Examples of reliable methods include use of oral contraceptives or Depo-Clinovir Contraceptive Injection (sterile medroxyprogesterone acetate suspension, Pharmacia), partner with vasectomy, diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, or intrauterine devices. Women who are pregnant or breast-feeding may not participate in the study.
- Educational level and degree of understanding such that they can communicate intelligibly with the investigator and study coordinator.
- Judged to be reliable and agrees to keep all appointments for clinic visits, tests, and procedures required by the protocol.
- Exclusion criteria:
- Have already a diagnosis of Depression and are currently treated with an antidepressant medication for depression, when entering the study.
- Suffer from pain that cannot be clearly differentiated from or conditions that interfere with the assessment of DPNPain.
- Had a historical exposure to drugs known to cause neuropathy, that could have been responsible for neuropathy.
- Have previously been treated with duloxetine (for DPNP or MDD)
- Are judged to be at suicidal risk by the clinical investigator or as defined by a score of 2 or greater on question 9 of the Beck Depression Inventory-II (BDI-II).
- Had a history of substance abuse or dependence within the past year, excluding nicotine and caffeine.
Exclusion
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00844194
Start Date
February 1 2009
Last Update
May 15 2014
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
1208.34.49008 Boehringer Ingelheim Investigational Site
Achim Bei Bremen, Germany
2
1208.34.49025 Boehringer Ingelheim Investigational Site
Aschaffenburg, Germany
3
1208.34.49001 Boehringer Ingelheim Investigational Site
Bad Mergentheim, Germany
4
1208.34.49018 Boehringer Ingelheim Investigational Site
Baesweiler, Germany